Oncos Therapeutics Increases Clinical Momentum With Appointment of Chief Medical Officer

February 9, 2011

HELSINKI, February 9, 2011 /PRNewswire/ — Oncos Therapeutics, a biotech
company developing novel cancer therapeutics based on its next generation
oncolytic viruses, announced today the appointment of Dr. Mikael von Euler,
MD, PhD, FFPM, as Chief Medical Officer. Earlier this year, the Company
announced the appointments of Dr. Jonathan Knowles and Dr. Robert Burns to
its Board of Directors.

“Oncos has already treated over 200 patients across different solid tumor
types with many different formulations of its next generation oncolytic
viruses – and this has created a unique platform of patient response data
from which the company can now build the highest quality data-driven clinical
development program,” comments Mikael von Euler.Mikael is a clinical
development professional and a seasoned oncology executive, bringing more
than 20 years of pharmaceutical industry experience in senior roles. Most
recently with Roche during 2007-2010, Mikael first held global clinical
responsibility for the HER family of compounds including Herceptin,
pertuzumab and Tarceva. As part of the Oncology Leadership Team, Mikael acted
in 2009-2010 as a Cluster Head for the HER2 Franchise. Prior to Roche, Mikael
was Vice President, Oncology MDC, Europe, at GlaxoSmithKline. Prior to
GlaxoSmithKline, he worked across several key clinical development roles at
AstraZeneca from 1995-2005, including Director of Clinical Strategy in Japan
and Global Product Director Oncology, working with products including
Arimidex, Zoladex, Nolvadex, Faslodex and Iressa. Mikael is an oncologist and
PhD from Karolinska Institutet and a Fellow of the Faculty of Pharmaceutical
Medicine of the Royal Colleges of Physicians, UK.

“Mikael brings a wealth of clinical development and regulatory expertise
to Oncos and he will have a key role in turning our Advanced Therapy Access
Program and the virus platform into a clinical development program,” comments

Pekka Simula, CEO and Co-Founder of Oncos Therapeutics.

About Oncos Therapeutics

Oncos Therapeutics develops novel cancer therapies based on its next
generation oncolytic viruses. The company’s unique Advanced Therapy Access
Program was started in 2007 for cancer patients in whom standard-of-care
therapies have failed. Today, over 200 patients have undergone individually
tailored oncolytic virus therapy suggesting strong safety and efficacy. The
program is based on scientific research at the University of Helsinki and
serves as the foundation for ongoing clinical development with company’s lead
agent CGTG-102, selected from the total of ten viruses used. Oncos
Therapeutics publishes an oncolytic virus blog
http://oncolyticvirus.wordpress.com. For more information about Oncos visit

SOURCE Oncos Therapeutics

Source: newswire

comments powered by Disqus